Engineered immune cells take on multiple sclerosis and other autoimmune brain diseases
NCT ID NCT07337785
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the immune system in people with neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and autoimmune encephalitis. The main goal is to check if the treatment is safe and to find the right dose. About 24 to 36 adults aged 18 to 70 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS (AE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Can tracking daily life unlock myasthenia gravis mysteries?
- Could a simple injection replace an IV for MS treatment?
- Can a new MRI scan reveal the Brain's hidden repair process in MS?